NSNobuhiro Sakai

Nobuhiro Sakai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nobuhiro Sakai has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Masamichi Takami

    Department of Pharmacology, Graduate School of Dentistry, Showa Medical University, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa Medical University, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan

    11 shared publications
  • Akiko Karakawa

    Department of Pharmacology, Showa Medical University Graduate School of Dentistry, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa Medical University, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan

    5 shared publications
  • Masahiro Chatani

    Department of Pharmacology, Graduate School of Dentistry, Showa University, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan

    5 shared publications
  • Yuki Azetsu

    Showa Univ, Grad Sch Dent, Dept Pharmacol, 1-5-8 Hatanodai, Shinagawa, Tokyo 1428555, Japan

    5 shared publications
  • Akiko Karakawa

    Department of Pharmacology, Showa University School of Dentistry, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan

    3 shared publications
  • Masahiro Chatani

    Department of Pharmacology, Graduate School of Dentistry, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan

    3 shared publications

Latest Publications

  • Synergistic effects of estrogen deficiency and articular disk derangement on condylar bone loss

    by Kazuhiro Shibusaka, Soichiro Negishi, Nobuhiro Sakai, Youngkwan Kim, Hiroyuki Okada, Fumiko Yano


  • Abnormal bone regeneration induced by FK506 in medaka fin revealed by in vivo imaging

    by Kai Otake, Yuki Azetsu, Masahiro Chatani, Akiko Karakawa, Satoko Nishida, Aiko Hirayama, Rina Kobayashi, Nobuhiro Sakai, Noriyuki Suzuki, Masamichi Takami


  • Tacrolimus, FK506, promotes bone formation in bone defect mouse model

    by Satoko Nishida, Yuki Azetsu, Masahiro Chatani, Akiko Karakawa, Kai Otake, Hidemitsu Sugiki, Nobuhiro Sakai, Yasubumi Maruoka, Mie Myers, Masamichi Takami


  • Planar catechin increases bone mass by regulating differentiation of osteoclasts in mice

    by Daiki Sugawara, Nobuhiro Sakai, Yurie Sato, Yuki Azetsu, Akiko Karakawa, Masahiro Chatani, Mirei Mizuno, Yasubumi Maruoka, Mie Myers, Kiyoshi Fukuhara, et al.


  • Effects of anti-RANKL antibodies administered to pregnant mice on bone and tooth development in neonates

    by Maho Yamaguchi, Masamichi Takami, Yuki Azetsu, Akiko Karakawa, Masahiro Chatani, Takahiro Funatsu, Nobuhiro Sakai


  • Double-Stranded RNA Induces Mortality in an MDA5-Mediated Type I Interferonopathy Model

    by Francine Lianne Emralino, Saya Satoh, Nobuhiro Sakai, Masamichi Takami, Fumihiko Takeuchi, Nan Yan, Frank Rutsch, Takashi Fujita, Hiroki Kato

    Gain-of-function mutations in the viral dsRNA sensor melanoma differentiation–associated protein 5 (MDA5) lead to autoimmune IFNopathies, including Singleton–Merten syndrome (SMS) and Aicardi–Goutières syndrome. However, much remains unclear regarding the mechanism of disease progression and how external factors such as infection or immune stimulation with vaccination can affect the immune response. With this aim, we generated mice with human MDA5 bearing the SMS-associated mutation R822Q (hM-R822Q). hM-R822Q transgenic (Tg) mice developed SMS-like heart fibrosis, aortic valve enlargement, and aortic calcification with a systemic IFN-stimulated gene signature resulting in the activation of the adaptive immune response. Although administration of the viral dsRNA mimic polyinosinic-polycytidylic acid [poly(I:C)] did not have remarkable effects on the cardiac phenotype, dramatic inflammation was observed in the intestines where IFN production was most elevated. Poly(I:C)-injected hM-R822Q Tg mice also developed lethal hypercytokinemia marked by massive IL-6 levels in the serum. Interrupting the IFN signaling through mitochondrial antiviral signaling protein or IFN-α/β receptor alleviated hM-R822Q–induced inflammation. Furthermore, inhibition of JAK signaling with tofacitinib reduced cytokine production and ameliorated mucosal damage, enabling the survival of poly(I:C)-injected hM-R822Q Tg mice. These findings demonstrate that the MDA5 R822Q mutant introduces a critical risk factor for uncontrollable inflammation on viral infection or vaccination.


  • Open Access

    Cholesterol and fat in diet disrupt bone and tooth homeostasis in mice

    by Yurie Sato, Masahiro Hosonuma, Daiki Sugawara, Yuki Azetsu, Akiko Karakawa, Masahiro Chatani, Takahiro Funatsu, Masamichi Takami, Nobuhiro Sakai


  • Open Access

    POS0429 INTERLEUKIN-4 ACTIVATES EOSINOPHILS AND CCR3-POSITIVE T HELPER CELLS MIGRATION TO FASCIA AND PROMOTES FIBROSIS IN EOSINOPHILIC FASCIITIS

    by M. Hosonuma, T. Isozaki, H. Furuya, Y. Yamazaki, Y. Ikari, S. Nishimi, A. Maeoka, S. Ishii, T. Tokunaga, K. Wakabayashi, et al.

    Background: Eosinophilic fasciitis (EF) is a rare disease that causes inflammation and fibrosis mainly in the fascia of the extremities with eosinophilia. It has been reported that the hypertrophied fascia in EF shows inflammatory cell infiltration by the lymphocytes and eosinophils and increased expression of fibrosis-related cytokines genes in fibroblast [1]. However, its pathophysiology in the fascia remains unresolved. Objectives: Therefore, we focused on fascial fibroblasts and aimed to determine the role of interleukin-4 (IL-4) in eosinophil and helper T cell infiltration and fibrosis in fascial fibroblast in EF. Methods: Fascial fibroblasts were obtained from fascia biopsy of a patient with EF, and were stimulated with pre- and post-treatment serum of a patient with EF and healthy control, followed by microarray to analyze gene expression. Fascial fibroblasts were stimulated with IL-4 10 ng/mL, and gene expression of IL-4 receptor and CCR3 ligands, CCL7 and CCL11 were measured by qPCR. Transforming growth factor (TGF) -β and periostin in the pre- and post-treatment serum of a patient with EF and conditioned medium of fascial fibroblasts stimulated with IL-4 were measured by ELISA. To examine the role of IL-4 in proliferation, we performed in proliferation assays using fascial fibroblasts treated with IL-4. CCR3-positive T cells in the fascial tissue of EF, dermatomyositis, and polymyositis patients were evaluated by immunostaining. Results: By microarray analysis, CCL7 and CCL11 expression of fascial fibroblasts stimulated with pre-treatment EF serum was higher than that in post-treatment EF serum and control serum. CCL7 and CCL11 mRNA in IL-4 stimulated facial fibroblasts were increased by 5.1-fold and 7.3-fold, respectively. TGF-β and periostin in IL-4 stimulated facial fibroblast conditioned medium were also increased. In addition, TGF-β and periostin in EF serum were gradually decreased by treatment for 4 and 10 weeks, compared to before treatment. Finally, fascial fibroblast proliferation was significantly increased by stimulation with IL-4. Furthermore, infiltration of CCR3-positive T cells was specific to the fascial tissue of EF. Conclusion: In EF, IL-4 enhances the production of CCR3 ligands, TGF-β, and periostin from fascial fibroblasts. As a result, it promotes the migration of eosinophils and CCR3-positive T helper cells to the fascia and fibrosis. These results suggest that inhibition of IL-4 pathway could be a novel strategy for eosinophilic fasciitis. References: [1]Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol. 1996 Apr;106(4):729-33. Disclosure of Interests: None declared


  • Open Access

    SAT0005 INHIBITION OF HEPATOCYTE GROWTH FACTOR/C-MET SIGNALING ABROGATES JOINT DESTRUCTION BY SUPPRESSING MIGRATION OF MONOCYTES TO SYNOVIUM IN RHEUMATOID ARTHRITIS

    by M. Hosonuma, N. Sakai, H. Furuya, Y. Tsubokura, S. Nishimi, Y. Ikari, S. Ishii, A. Maeoka, T. Tokunaga, K. Wakabayashi, et al.

    Background: Hepatocyte growth factor (HGF), originally discovered as a mitogen of hepatocytes, binds to receptor-tyrosine kinase c-Met and has been shown to be a multi-functional cytokine that promotes processes such as cell proliferation, survival, differentiation, migration, and angiogenesis1. Since HGF/c-Met signaling also leads to tumorigenesis and cancer invasion, that has recently attracted attention as a target for anticancer agents2. However, in reports of rheumatoid arthritis (RA), though anti-inflammatory and antiangiogenic mechanisms related to HGF/c-Met signal inhibition have been reported, the role of HGF in RA bone destruction through monocyte migration remains unclear3. Objectives: To determine the expression of HGF in RA biological fluids, the role it plays in monocyte migration and the therapeutic effect of a savolitinib, a specific c-Met inhibitor, in arthritis model mice. Methods: HGF/c-Met expression in serum, synovial fluid (SF), and synovial tissues (STs) obtained from RA patients and control subjects, as well as RA fibroblast-like synoviocytes (FLSs) was evaluated by ELISA and immunostaining. To determine the function of HGF in RA SFs, we preincubated RA SFs with a neutralizing anti-HGF antibody and measured the ability of these SFs to induce the human acute monocytic leukemia cell line (THP-1) chemotaxis. Additionally, examinations of SKG mice treated with savolitinib (2.5 mg/kg/day) for 4 weeks were conducted. Results: HGF level in serum from RA patients was significantly higher as compared to the controls (930 ± 97 vs. 476 ± 97 pg/mL, p Conclusion: HGF is produced by inflammation in synovium associated with RA, and then activates monocyte migration to synovium tissue and promotes bone destruction through its own chemotactic effect as well as enhanced chemokine production. These results indicate that a strategy that targets c-Met signaling may be important for resolving bone destruction in RA. References: [1] Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989 Nov 23;342(6248):440-3 [2] Lee D, Sung ES, Ahn JH, An S, Huh J, You WK. Development of antibody-based c-Met inhibitors for targeted cancer therapy. Immunotargets Ther. 2015 Feb 9;4:35-44. [3] Koch AE, Halloran MM, Hosaka S, Shah MR, Haskell CJ, Baker SK, Panos RJ, Haines GK, Bennett GL, Pope RM, Ferrara N. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum. 1996 Sep;39(9):1566-75 Disclosure of Interests: None declared

  • Effects of N-methyl-d-aspartate receptor antagonist MK-801 (dizocilpine) on bone homeostasis in mice

    by Shuichi Kiyohara, Nobuhiro Sakai, Kazuaki Handa, Tomoyuki Yamakawa, Koji Ishikawa, Masahiro Chatani, Akiko Karakawa, Yuki Azetsu, Motohiro Munakata, Masahiko Ozeki, et al.